SOAT1 and glioblastoma: Conversely, disruption of constitutively activated JAK/STAT signaling results in a reduction in the CSC population and loss of tumorigenicity in vivo in a wide range of cancers, such as ovarian [30], prostate [31], glioblastoma [29], and esophageal squamous [32] cancer.